Biocon's Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

Shaw was picked from among 46 award winners from 41 countries and territories vying for the global title

Kiran Mazumdar-Shaw, Biocon
EY, in its felicitation, said Shaw had been at the forefront of innovation through her strong investments in research
Samreen Ahmad Bengaluru
2 min read Last Updated : Jun 05 2020 | 10:13 PM IST
Biocon’s Executive Chairperson Kiran Mazumdar-Shaw has been named EY World Entrepreneur Of The Year 2020, becoming the third Indian to win the title. Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys are the other title winners from India.
 
Shaw was picked from among 46 award winners from 41 countries and territories vying for the global title.
 
“At its core, entrepreneurship is about solving problems. The greatest opportunities often arise at the toughest times, and that’s been my experience throughout my entrepreneurial journey. My business focus is global health care and the provision of universal access to life-saving medicine; however, my responsibility as an entrepreneur is greater than simply delivering value to shareholders,” said Shaw on winning the award.
 
“I feel so humbled and proud that I won it for my colleagues and my country,” she tweeted on Friday.
 
The Bengaluru-based company, founded in 1978 with $500, has now a market capitalisation of over $4 billion.
 
In its fight against Covid-19, Biocon’s research arm Syngene, which has developed Elisa antibody test kits for Covid-19, has tied up with biosciences HiMedia Laboratories for manufacturing and distribution of the kits. While the biopharmaceutical major recently got DCGI approval to use CytoSorb device for treatment of Covid-19 patients, it has received the regulatory nod to repurpose its psoriasis drug Itolizumab to treat the virus in moderate to severe patients.
 
“Right now, the world is looking for solutions to prevent infection with SARS-CoV-2 and treat patients with Covid-19. As the founder of a global biopharmaceutical company, I am contributing to worldwide efforts to tackle Covid-19 through innovative science,” said Shaw.
 
EY, in its felicitation, said Shaw had been at the forefront of innovation through her strong investments in research.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Kiran Mazumdar-ShawBiocon

Next Story